Responder criteria after 12 weeks of therapy by treatment group
| Treatment group | |||
|---|---|---|---|
| Responder criteria | Placebo (n=43) | Etanercept (n=39) | p Value |
| ASAS20 | 14 (33%) | 25 (67%) | 0.003 |
| ASAS40 | 10 (23%) | 17 (44%) | 0.053 |
| ASAS5/6 | 2 (5%) | 8 (21%) | 0.044 |
| ASAS partial remission | 2 (5%) | 7 (18%) | 0.073 |
| BASDAI 50 | 10 (23%) | 18 (46%) | 0.031 |
| ASDAS-CRP changes (W12-baseline) | |||
| Δ ASDAS ≥1.1 (minimally important improvement) | 7 (17.1) | 25 (64.1) | <0.0001 |
| Δ ASDAS ≥2.0 (major improvement) | 1 (2.4) | 15 (38.5) | <0.0001 |
| ASDAS-CRP status at W12 | |||
| ASDAS <1.3 | 35 (85.4) | 17 (43.6) | <0.001 |
| ASDAS <2.1 | 41 (100) | 25 (64.1) | <0.0001 |
ASAS, Ankylosing Spondylitis Activity Score; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index.